Hence, early testing and prediction of potential immunogenicity and allergenicity caused by these drugs is essential, but can be quite challenging. Hosted by The Scientist, this live webinar brings ...

A new article argues dystrophin immunogenicity is an under-examined issue in the treatment of Duchenne muscular dystrophy.

In the immuno-oncology field, scientists discover, test, and validate novel immunotherapeutic agents ... researchers must evaluate a treatment’s immunogenicity, which includes a broad spectrum of ...

The FDA's announcement marks a significant advancement in regulatory modernization and aligns fully with ImmunoPrecise's mission to revolutionize drug discovery and development processes through ...